Literature DB >> 15875171

Twenty-four hour tolbutamide plasma concentration as a phenotypic measure of CYP2C9 activity.

Craig R Lee, Roy L Hawke, John A Pieper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15875171     DOI： 10.1007/s00228-005-0922-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  6 in total

1.  Discovery of new potentially defective alleles of human CYP2C9.

Authors:  Joyce Blaisdell; Lucia F Jorge-Nebert; Sherry Coulter; Stephen S Ferguson; Su-Jun Lee; Brian Chanas; Tina Xi; Harvey Mohrenweiser; Burhan Ghanayem; Joyce A Goldstein
Journal:  Pharmacogenetics       Date:  2004-08

2.  Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers.

Authors:  M E Veronese; J O Miners; D Randles; D Gregov; D J Birkett
Journal:  Clin Pharmacol Ther       Date:  1990-03       Impact factor: 6.875

3.  Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

Authors:  Craig R Lee; John A Pieper; Alan L Hinderliter; Joyce A Blaisdell; Joyce A Goldstein
Journal:  Clin Pharmacol Ther       Date:  2002-11       Impact factor: 6.875

4.  Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

Authors:  Julia Kirchheiner; Steffen Bauer; Ingolf Meineke; Wolfgang Rohde; Verena Prang; Christian Meisel; Ivor Roots; Jürgen Brockmöller
Journal:  Pharmacogenetics       Date:  2002-03

5.  Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.

Authors:  Craig R Lee; John A Pieper; Reginald F Frye; Alan L Hinderliter; Joyce A Blaisdell; Joyce A Goldstein
Journal:  J Clin Pharmacol       Date:  2003-01       Impact factor: 3.126

6.  Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.

Authors:  Alexander Jetter; Martina Kinzig-Schippers; Andreas Skott; Andreas Lazar; Dorota Tomalik-Scharte; Julia Kirchheiner; Monika Walchner-Bonjean; Ursula Hering; Verena Jakob; Michael Rodamer; Wafaâ Jabrane; Dirk Kasel; Jürgen Brockmöller; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2004-03-25       Impact factor: 2.953
  6 in total
  1 in total

1.  Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.

Authors:  Anna Nordmark; Anita Andersson; Pawel Baranczewski; Ewa Wanag; Lars Ståhle
Journal:  Eur J Clin Pharmacol       Date:  2013-11-02       Impact factor: 2.953
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.